This nationwide, population-based cross-sectional study aimed to assess the prevalence of liver steatosis and fibrosis in both the general population and high-risk groups in China, using data from...
Miu Lai (Milly) Ng,
FNP-BC, MPH (Harvard)
Nurse Practitioner, Tufts Medical Center
During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...
NASH Becoming Leading Cause for Liver Transplantation
Nonalcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation in the US. However, patients with NASH face...
In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...
